WallStSmart

Merck & Company Inc (MRK)vsSonida Senior Living Inc (SNDA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 17804% more annual revenue ($65.77B vs $367.34M). MRK leads profitability with a 13.6% profit margin vs -27.1%. SNDA appears more attractively valued with a PEG of 2.04. MRK earns a higher WallStSmart Score of 50/100 (D+).

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.30

SNDA

Hold

39

out of 100

Grade: F

Growth: 6.7Profit: 2.0Value: 4.7Quality: 3.0
Piotroski: 2/9Altman Z: -0.49
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-49.3%)

Margin of Safety

-49.3%

Fair Value

$80.88

Current Price

$120.79

$39.91 premium

UndervaluedFair: $80.88Overvalued

Intrinsic value data unavailable for SNDA.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$285.64B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

SNDA2 strengths · Avg: 9.0/10
Revenue GrowthGrowth
38.5%10/10

Revenue surging 38.5% year-over-year

Price/BookValuation
1.8x8/10

Reasonable price relative to book value

Areas to Watch

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

SNDA4 concerns · Avg: 3.3/10
PEG RatioValuation
2.044/10

Expensive relative to growth rate

Market CapQuality
$1.73B3/10

Smaller company, higher risk/reward

Debt/EquityHealth
1.833/10

Elevated debt levels

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : SNDA

The strongest argument for SNDA centers on Revenue Growth, Price/Book. Revenue growth of 38.5% demonstrates continued momentum.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Bear Case : SNDA

The primary concerns for SNDA are PEG Ratio, Market Cap, Debt/Equity. Debt-to-equity of 1.83 is elevated, increasing financial risk.

Key Dynamics to Monitor

MRK profiles as a value stock while SNDA is a hypergrowth play — different risk/reward profiles.

SNDA carries more volatility with a beta of 0.78 — expect wider price swings.

SNDA is growing revenue faster at 38.5% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 39/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Sonida Senior Living Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Sonida Senior Living, Inc. develops, owns, operates and manages senior living communities in the United States. The company is headquartered in Dallas, Texas.

Want to dig deeper into these stocks?